Quick Answer
Neumora Therapeutics, Inc. reported Operating Income of -$241.16 million for fiscal year 2025.
Neumora Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$241.16M | +8.5% |
| 2024 | -$263.46M | -4.5% |
| 2023 | -$252.10M | -85.5% |
| 2022 | -$135.87M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$57.70M | +24.7% | -6.8% |
| June 30, 2025 | -$54.04M | +15.3% | +23.8% |
| March 31, 2025 | -$70.94M | -18.1% | +7.4% |
| September 30, 2024 | -$76.65M | -34.8% | -20.1% |
| June 30, 2024 | -$63.82M | -51.7% | -6.2% |
| March 31, 2024 | -$60.07M | -53.4% | -5.6% |
| September 30, 2023 | -$56.86M | -85.8% | -35.2% |
| June 30, 2023 | -$42.06M | — | -7.4% |
- Neumora Therapeutics, Inc. showed an increase of +8.5% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Neumora Therapeutics, Inc.’s operating income has declined by 77.5% (from -$135.87 million to -$241.16 million).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: